The evolution of bladder cancer genomics: What have we learned and how can we use it?

Audenet, François; Attalla, Kyrollis; Sfakianos, John P.

doi:10.1016/j.urolonc.2018.02.017

Cited by 85 publications

(87 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Molecular data from TCGA BLCA cohort can be considered representative of invasive BLCA and serve as a valuable resource to validate prognostic biomarkers . Next‐generation sequencing can identify potential targets in bladder cancer for predictive value and personalized therapy . Our research selected nine different algorithms based on the above principles to identify potential driver genes of bladder cancer based on DNA sequencing data from the TCGA‐BLCA Project.…”

Section: Introductionmentioning

confidence: 99%

Identification of a nine‐gene panel as a prognostic indicator for recurrence with muscle‐invasive bladder cancer

Han

Zheng

Tian

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives Bladder cancer is one of the most common and highly recurrent cancers worldwide. Recurrence‐associated genes may potentially predict cancer recurrence. We aimed to construct a recurrence‐associated gene panel to improve the prognostic prediction of bladder cancer. Methods Based on DNA sequencing and clinical data from the TCGA‐BLCA project, we identified 10 potential driver genes significantly associated with recurrence of bladder cancer. We performed multivariable logistic regression analysis to construct an optimized recurrence prediction model with nine recurrence‐associated genes (EME1, AKAP9, ZNF91, PARD3, STAG2, ZFP36L2, METTL3, POLR3B, and MUC7) and clinical information as the independent variables. Results The area under the receiver operating characteristic (ROC) curve was 0.80 in this model, much higher than that of the baseline model (AUC = 0.73) and the same trend was also validated in its subset. Decision curve analysis also revealed that there is a significant net benefit gained by adding nine genes mutation to the baseline model. Furthermore, Kaplan‐Meier survival analysis showed that eight out of the nine genes (excluding MUC7) had good effects on the overall prognosis of patients. Conclusions This nine‐gene panel will most likely be a useful tool for prognostic evaluation and will facilitate the personalized management of patients with bladder cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of a nine‐gene panel as a prognostic indicator for recurrence with muscle‐invasive bladder cancer

Han

Zheng

Tian

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…With the development of molecular biology approaches, the processes of urothelial carcinoma pathogenesis have been widely and deeply explored. We have classi ed bladder cancer by gene sequencing and comprehensive pro ling of RNA expression and have used DNA sequencing results from biopsy to understand survival distributions and prognostic factors [53][54][55]. This new understanding of heterogeneous diseases such as UT-UUC and bladder cancer can lead to improved outcomes and quality of life through better-customized treatments.…”

Section: Discussionmentioning

confidence: 99%

The predictive value of preoperative positive urine cytology for development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma: A retrospective multi-center case-control study and meta-analysis

Fan

Huang

Wen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Upper urinary tract urothelial carcinoma (UUT-UC) is a rare and severe urinary malignancy. Urine cytology is a common clinical method for the early diagnosis of urologic neoplasms. Several studies have explored the relationship between preoperative urine cytology and intravesical recurrence in patients with UUT-UC. However, the results of these studies are controversial or even contradictory, and investigations with UUT-UC patients in Northeast China are rare. Methods: In this retrospective case-control study, we first estimated the prognostic significance of preoperative urine cytology in the outcomes of intravesical recurrence in 142 patients with UUT-UC after radical nephroureterectomy (RNU). A nomogram model was established and we evaluated its effectiveness. Subsequently, after searching several databases, including PubMed, Embase, and Ovid, we quantitatively combined our results with the published data in a meta-analysis. Results: Our case-control study demonstrated that patients with muscle-invasive tumors (T2-T4) were more prone to preoperative positive urine cytology than those with non-muscle-invasive tumors (Tis-T1), suggesting that preoperative positive urine cytology may be associated with the aggressive form of UUT-UC. Kaplan-Meier curves demonstrated that the patients with positive urine cytology had significantly poorer intravesical recurrence-free survival (IV-RFS). Additionally, preoperative urine cytology (hazard ratio, HR=3.24) and lymph node status (HR=2.67) were validated as significant independent predictors of intravesical recurrence by multivariate analysis. Nomogram, calibration plots, AUC values and the C-index demonstrated that the predictive accuracy was significantly improved when preoperative urine cytology was combined. Subsequently, adding to our study, 11 eligible articles from 2010 to 2016 containing 2942 patients were sifted out for our meta-analysis. Overall analysis showed that preoperative positive urine cytology was associated with a 56% increased risk of intravesical recurrence (HR=1.56). In the subgroup analysis by region, study type, and sample size, the pooled HR was statistically significant for the Japan subgroup (HR=1.45), China subgroup (HR=1.66), cohort study subgroup (HR=1.44), and case-control study subgroup (HR=1.77), the subgroup with sample size greater than or equal to 100 (HR=1.42), and the subgroup with sample size less than 100 (HR=2.95). Conclusions: Preoperative urine cytology significantly correlated with intravesical recurrence in patients with UUT-UC after RNU, although these results need to be interpreted with caution. Large, prospective trials are required to further confirm its prognostic significance.

show abstract

“…In recent times, the wide-spreading technology of gene testing may allow to predict organs that are likely to metastasize. Genome-based molecular is one of the potential biomarkers for phenotype classification [ 46 – 49 ]. The basal type of MIBC is associated with worse disease-specific and OS due to its highly invasive and metastatic potential [ 46 ].…”

Section: Risk Factors For Symptomatic Recurrencementioning

confidence: 99%

Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma

2018

View full text Add to dashboard Cite

For the management of muscle-invasive bladder cancer or upper tract urothelial carcinoma, the set guidelines recommend regular surveillance after radical cystectomy or radical nephroureterectomy. However, the prognostic benefit of regular oncological surveillance remains controversial in the absence of prospective studies although several retrospective studies with relatively large sample sizes have demonstrated the association between asymptomatic recurrence and better oncological outcomes. Seven out of eight studies reported that patients diagnosed with symptomatic recurrence showed significantly poorer prognosis in comparison to those diagnosed with asymptomatic recurrence. However, potential lead-time and length-time biases prevent the determination of any benefit of regular surveillance. In addition, an optimal surveillance protocol has yet to be established because conventional pathology-based protocols cannot identify the heterogenetic tumor biology of urothelial carcinoma, such as rapid- or slow-growing form of the disease. Several studies suggest that conventional pathology-based surveillance resulted in reduced cost-effectiveness. Recurrence risk-score stratified surveillance protocol including clinical and pathological factors may improve cost-effectiveness. The establishment of optimal risk stratification and surveillance strategies are required to improve the efficacy of regular oncological surveillance. Well-planned prospective studies are necessary to address the prognostic benefit of regular oncological surveillance and shared decision making.

show abstract

The evolution of bladder cancer genomics: What have we learned and how can we use it?

Cited by 85 publications

References 50 publications

Identification of a nine‐gene panel as a prognostic indicator for recurrence with muscle‐invasive bladder cancer

Identification of a nine‐gene panel as a prognostic indicator for recurrence with muscle‐invasive bladder cancer

The predictive value of preoperative positive urine cytology for development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma: A retrospective multi-center case-control study and meta-analysis

Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma

Contact Info

Product

Resources

About